Other ADCs that also showed promising IC activities including patritumab deruxtecan (HER3-DXd) targeting HER-3 for third-line treatment in EGFR-mutated advanced NSCLC [63], and datopotamab deruxtecan (Dato-DXd) targeting Trop-2 for previously treated advanced NSCLC with AGAs, etc. [64]. This evidence concerns the gene TACSTD2 and non-small cell lung carcinoma.